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Abstract
Background: CCNU and other treatment protocols are commonly offered to owners for the treatment of
dogs diagnosed with cutaneous (epitheliotropic) T-cell lymphoma (CTCL). Chemotherapy protocols provide
variable benefits; they have different side-effects, and they typically require monitoring to detect drug toxicity at a non-
negligible cost to the owner. At this time, even though CCNU is most often recommended to treat dogs with CTCL,
there is no clear consensus on the benefit of this drug. Knowing which chemotherapy protocol yields the highest rate
of complete remission and longest survival times would help veterinarians and pet owners select treatment options
based on the best evidence available. Our objective was to review the literature to compare the complete remission
rates and survival times of CCNU-based protocols to those of other interventions. We critically assessed the
data included in articles reporting treatment outcome in at least five dogs with CTCL. Single case reports
and case series with less than five patients were not reviewed to avoid anecdotal evidence of lower quality.
Results: The search for, and review and analysis of, the best evidence available as of February 8, 2017, suggests
that CCNU and pegylated liposomal doxorubicin appear to yield the highest rate of complete remission in
approximately one-third of dogs with CTCL. Other treatment protocols did not report usable information on
remission rates. Without any treatment, the mean/median survival time in dogs with CTCL varied between
3 and 5 months. With CCNU protocols, the median survival time was 6 months and the one with retinoids
(isotretinoin and/or etretinate), PEG L-asparaginase or prednisolone monotherapy was 11, 9 and 4 months,
respectively; all these durations were obtained from small numbers of dogs, however.
Conclusions: CCNU leads to a complete remission of signs in approximately one-third of dogs with CTCL,
but such remissions are of short duration. The median survival time after CCNU appears longer than that
without treatment, but other drugs appear to provide a better long-term prognosis. Further studies are required to
investigate the effect of CCNU, alone or in combination, on remission rates, survival times and impact on quality of life.
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Background
Lomustine (CCNU) or other chemotherapy protocols are
commonly offered to owners for the treatment of their
dogs diagnosed with cutaneous (epitheliotropic) T-cell
lymphoma (CTCL). Although these regimens are expected
to lead to a temporary partial or complete remission (CR)
of skin lesions, monitoring for the detection of common
severe adverse events requires regular laboratory
monitoring that might represent a significant finan-
cial burden to the clients [1]. At this time, there is no
clear consensus on the benefit of the various treat-
ment regimens for dogs with CTCL.
Knowing which chemotherapy protocol has the strongest
evidence for yielding the best complete remission rates and
longest survival times would help veterinarians and pet
owners select treatment options based on the best evidence
available. Our objective was to review the literature to com-
pare the complete remission rates and survival times of
CCNU-based protocols to those of other interventions.
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Clinical scenarios
You have two patients: The first one is a 5-year-old
female Labrador retriever crossbred dog. The owners re-
port that the lesions started 2.5 months beforehand and
that they consisted, at first, of generalized scaling and
pruritus. They evolved into multifocal areas of truncal
alopecia and erythema along with an ulcer on the caudal
abdomen. The dog was placed on a tapering course of
prednisone that led to a reduction in clinical signs. After
discontinuing the steroids, the dog developed alopecic
erythematous macules, patches and plaques, and she be-
came more pruritic than before.
Your second patient is a 12-year-old male golden
retriever presenting with multifocal large patchy areas
of hypopigmentation and depigmentation along with
multifocal erythematous plaques and nodules. The
owner reports that the dog may have had depigmen-
ted muzzle lesions for the past 2 years.
In both cases, skin biopsies confirmed your suspicion
of CTCL. You wonder which chemotherapeutic option
would be most beneficial for these two dogs.
Structured question
In a dog with CTCL, which chemotherapeutic treatment
protocol would be most effective to induce the CR of clinical
signs and to lead to the longest survival?
Methods
Search strategy
The CAB Abstracts and Web of Science (WoS) Science
Citation Index Expanded databases were searched on
April 26, 2016 for relevant articles using the following
string: (dog or dogs or canine) and (cutaneous or
epitheliotropic or epidermotropic) and (lymphoma or
lymphosarcoma) and (CCNU or lomustine or vincris-
tine or cyclophosphamide or chlorambucil or predniso*
or chemotherap*). The search was limited to the period
1980–2016. We then screened the bibliographies of
identified articles for additional relevant reports. At the
time of revision of this manuscript (Febuary 08, 2017),
a second broad literature search was done to identify
papers published since the first search.
Results and discussion
Identified evidence
Our literature search found 63 and 65 articles in the
CAB Abstract and Web of Science (WoS) databases,
respectively. Citations were initially examined for the
identification of articles reporting the outcome of treat-
ment in dogs with CTCL diagnosed via histopathology.
We then evaluated abstracts, and articles with poten-
tially relevant information were read in full. The bibliog-
raphy of these papers was analyzed further for additional
pertinent reports.
We only selected articles that provided definite infor-
mation on the rate of CR /or survival times after diagno-
sis or treatment of at least five dogs with CTCL; articles
and information on partial remission were not reviewed
further.
Two retrospective [2, 3] and one prospective studies
[4] providing clear information on CR rates in dogs with
CTCL were found in both CAB and WoS databases.
One preclinical trial [5] and one pilot study [6] were
subsequently added following the review of the bibli-
ographies of articles identified in the electronic
searches. Finally, we added one last article that had
been published after the performance of our initial lit-
erature search [7].
For survival times after diagnosis or treatment, one
retrospective study [8] and one prospective study [9]
were identified in the CAB abstracts, one of which
was also found in the WoS [8]. A prospective [10]
and a retrospective study [11] were added following




The rates of CR in studies involving five or more dogs
were given for protocols using CCNU, pegylated lipo-
somal doxorubicin, the prodrug VDC-1101 (a guanine
analog) and masitinib (Table 1).
Altogether, CCNU, alone or in conjunction with other
concurrent medications, yielded a combined rate of CR
of 30% of the 87 dogs reported [2, 3, 6]. The median
duration of CR, estimated from only 15 dogs in one
article [2], was 132 days (range: 26–258 days). The
time to achieve CR was not identified in any article.
In one report of 46 dogs [2], the overall median num-
ber of treatments needed to observe a response (type
not specified) was one (range: one to six cycles).
A similar rate of CR occurred with pegylated liposomal
doxorubicin, but the number of dogs treated (nine) was
low [5]. The median duration of CR was shorter (90 days,
range: 21–340) than with CCNU; the time to CR was
not reported either.
The prednisone and VDC-1101 combination did
not lead to CR in any of the ten dogs to which it
was administered [4].
Finally, masitinib induced a CR of signs of CTCL in 2/
10 treated dogs (20%); this remission lasted for 126 days
in one dog and over 3 years in the other [7].
Survival times after diagnosis or treatment initiation
The survival times were only available for a few dogs
treated with each intervention (Table 2). Without any
treatment, the median survival time in dogs with CTCL
varied between 3 [11] and 5 months [8].
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The median/mean survival times were, in order of
decreasing durations, 11 months after treatment with
the retinoids isotretinoin and/or etretinate [9], 9 months
after PEG L-asparaginase [10], 6 months after CCNU
protocols [8] and 4 months after prednisolone alone [8].
Limitations
The main limitation of this compilation is that any
confounding effect of the dog’s age, CTCL severity,
CTCL stage or time before the diagnosis was made or
treatment initiated were not evaluated for their pos-
sible impact on CR or survival times in any of these
studies. Another limitation is that CCNU was used
alone in only one-third of dogs in the largest case
series [2, 3], and the rates of CR were not compared
between dogs receiving CCNU monotherapy and those
treated with combination regimens. Furthermore, the
survival times provided were likely to have been influ-
enced by euthanasia decisions by the owner, thereby
not reflecting disease-induced death. Finally, many of
the estimates provided herein were only assembled
from a small number of patients.
Conclusions
Implications for practitioners
In spite of the limitations raised above, and taking into
consideration the best evidence available, CCNU pro-
tocols, when used alone or in combination with other
drugs, appear to lead to CR rates of 30%, but the
median duration of such CRs remains unclear. The
median survival time of CTCL after CCNU protocols
is 6 months following diagnosis. Retinoids or PEG L-
asparaginase appear to offer longer median survival
times, but these drugs are not routinely available.
At the time of this writing, CCNU—alone or in
combination with other drugs—appears to be a valu-
able option to treat dogs with CTCL; unfortunately,
the common occurrence of myelopoietic and/or
gastrointestinal side effects requires frequent blood
test monitoring that increases the cost of treatment.
Implication for research
Additional studies are needed to compare the rates of
CR and survival times using glucocorticoids, CCNU or
retinoids (e.g. bexarotene), either alone or in various
Table 1 Rates of complete remission in dogs with CTCL
CCNU Pegylated liposomal doxorubicin VDC-1101 and prednisone Masitinib
References N CR (N, %) N CR (N, %) N CR (N, %) N CR (N, %)
Morges, 2014 [4] 10 0 (0%)
Risbon, 2006 [2] 46a 15 (33%)
Williams, 2006 [3] 36 6b (33%)
Graham, 1999 [6] 5 5c (100%)
Vail, 1997 [5] 9 3 (33%)
Holtermann, 2016 [7] 10d 2 (20%)
TOTAL 87 26 (30%) 9 3 (33%) 10 0 (0%) 1- 2 (20%)
Abbreviations: CR complete remission, N number of dogs
a14 dogs received CCNU monotherapy, 27 also received glucocorticoids that were later either tapered, discontinued or maintained. The co-administration of prednisone
was reported not to be significantly associated with the response or its duration. Other concurrent medications included PEG L-asparaginase (6 dogs), essential fatty
acids (8), nonsteroidal anti-inflammatory drugs (3), retinoids (2), and interferon (1)
b67% of the dogs experiencing a CR also received concurrent glucocorticoids
c2 dogs may have received concurrent surgery
dthe response was assessed on the three most dominant “target” lesions
Table 2 Survival times in dogs with CTCL (in months)
CCNU Prednisolone Retinoidsa PEG L-asparaginaseb No treatment
References N S N S N S N S N S
Fontaine, 2010 [8]c 7 6 6 4 3 5
White, 1993 [9]c 5 11
Moriello, 1993 [10]d 7 9
Beale, 1993 [11]e 8 3
Abbreviations: N number, S median or mean survival times (in months) after diagnosis or treatment
athe concurrent use of glucocorticoids was allowed
bthree patients also received glucocorticoids, one patient was also treated with vincristine/cyclophosphamide and doxorubicin
cMost dogs were euthanized; the specific number of dogs was not specified
dAll dogs were euthanized
ethe number of dogs euthanized was not specified
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combinations thereof. Because of the potential toxicity
and side effects of CCNU, the quality of life in dogs
receiving CCNU protocols should be compared to that
without any treatment or with other medications. Future
studies should also attempt to compare CR rates and
survival times in dogs of various age groups as well as in
those with variable duration of clinical signs, stages or
severities of CTCL.
Abbreviations
CCNU: 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (i.e. lomustine); CR: complete





Availability of data and materials
The data analyzed during the current study are available from the
corresponding author on reasonable request.
Authors’ contributions
The two authors selected the topic of this CAT; AFL performed the literature
search, extracted and summarized the evidence; TO verified the evidence
and both authors contributed to the writing of this article.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not needed or relevant.
Ethics approval and consent to participate
Not needed or relevant.
Received: 12 November 2016 Accepted: 15 February 2017
References
1. Heading KL, Brockley LK, Bennett PF. CCNU (lomustine) toxicity in dogs: a
retrospective study (2002-07). Aust Vet J. 2011;89:109–16.
2. Risbon RE, de Lorimier LP, Skorupski K, Burgess KE, Bergman PJ, Carreras J,
Hahn K, Leblanc A, Turek M, Impellizeri J, Fred 3rd R, Wojcieszyn JW, Drobatz K,
Clifford CA. Response of canine cutaneous epitheliotropic lymphoma to
lomustine (CCNU): a retrospective study of 46 cases (1999-2004). J Vet Intern
Med. 2006;20:1389–97.
3. Williams LE, Rassnick KM, Power HT, Lana SE, Morrison-Collister KE, Hansen
K, Johnson JL. CCNU in the treatment of canine epitheliotropic lymphoma.
J Vet Intern Med. 2006;20:136–43.
4. Morges MA, Burton JH, Saba CF, Vail DM, Burgess KE, Thamm DH. Phase II
evaluation of VDC-1101 in canine cutaneous T-cell lymphoma. J Vet Intern
Med. 2014;28:1569–74.
5. Vail DM, Kravis LD, Cooley AJ, Chun R, MacEwen EG. Preclinical trial of
doxorubicin entrapped in sterically stabilized liposomes in dogs with
spontaneously arising malignant tumors. Cancer Chemother Pharmacol.
1997;39:410–6.
6. Graham JC, Myers RK. Pilot study on the use of lomustine (CCNU) for the
treatment of cutaneous lymphoma in dogs [abstract 125]. Proceedings of
the Proceedings of the 17th Annual Forum of the College of Veterinary
Internal Medicine. Chicago: American College of Veterinary Internal
Medicine; 1999.
7. Holtermann N, Kiupel M, Kessler M, Teske E, Betz D, Hirschberger J. Masitinib
monotherapy in canine epitheliotropic lymphoma. Vet Comp Oncol.
2016;14 Suppl 1:127–35.
8. Fontaine J, Heimann M, Day MJ. Canine cutaneous epitheliotropic T-cell
lymphoma: a review of 30 cases. Vet Dermatol. 2010;21:267–75.
9. White SD, Rosychuk RA, Scott KV, Trettien AL, Jonas L, Denerolle P. Use of
isotretinoin and etretinate for the treatment of benign cutaneous neoplasia
and cutaneous lymphoma in dogs. J Am Vet Med Assoc. 1993;202:387–91.
10. Moriello KA, Macewen G, Schultz KT. Peg L-asparaginase in the treatment of
canine epitheliotropic lymphoma and histiocytic proliferative dermatitis. In:
Ihrke PJ, Mason IS, White SD, editors. Advances in veterinary dermatology,
vol. 2. 1993. p. 293–9.
11. Beale KM, Bolon B. Canine cutaneous lymphosarcoma: epitheliotropic and
non-epitheliotropic, a retrospective study. In: Ihrke PJ, Mason IS, White SD,
editors. Advances in veterinary dermatology, vol. 2. New York: Pergamon
Press; 1993. p. 273–84.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Laprais and Olivry BMC Veterinary Research  (2017) 13:61 Page 4 of 4
